|February 3, 2014|
|07:12 EDT||RHHBY, PDLI||PDL BioPharma reaches agreement in litigation with Genentech and Roche |
PDL BioPharma (PDLI) has entered into an agreement with Genentech and F. Hoffmann-La Roche (RHHBY) which resolves all outstanding legal disputes between the parties, including its Nevada litigation with Genentech and Roche and its arbitration proceedings with Genentech related to the audit of royalties on sales. Under the terms of the agreement, effective retroactively to August 15, 2013, Genentech will pay a fixed royalty rate of 2.125% on worldwide sales of Avastin, Herceptin, Lucentis Xolair, Kadcyla and Perjeta. Genentech will pay these royalties on all worldwide sales of Avastin, Herceptin, Xolair, Perjeta and Kadcyla occurring on or before December 31, 2015. With respect to Lucentis, Genentech will owe no royalties on U.S. sales occurring after June 30, and will pay a royalty of 2.125% on all ex-U.S. sales occurring on or before December 28, 2014. PDL expects to recognize royalty revenue on the licensed products until Q1 2016. Additionally, the settlement terms provide for a better definition of revenues and audit inspection procedures related to the arbitration dispute filed by PDL. The settlement and the related agreement are conditional upon entry of a proposed order dismissing the underlying litigation and dismissal of the AAA arbitration filed by PDL.
News For PDLI;RHHBY From The Last 14 Days
|April 22, 2015|
|05:27 EDT||RHHBY||Roche sees FY15 core EPS to grow ahead of sales at constant exchange rates|
Expects FY15 sales to grow low- to mid-single digit, at constant exchange rates. Roche expects to further increase its dividend in Swiss francs.
|05:27 EDT||RHHBY||Roche reports Q1 group sales CHF 11.83B vs. CHF 11.50B|
Subscribe for More Information
|April 21, 2015|
|07:06 EDT||RHHBY||Bina Tech, AstraZeneca announce collaborative agreement for GMS|
Bina Technologies, a member of the Roche Group (RHHBY), and AstraZeneca (AZN) announced that they have entered into an agreement for AstraZeneca to become the first member to join the Bina Alliance Program and to further develop the Bina Genomic Management Solution. AstraZeneca will utilize the Bina GMS as an enterprise platform to support its development work across three main therapeutic areas: oncology, cardiovascular and metabolic disease, and respiratory, inflammation and autoimmunity. Bina’s proprietary technology enables translational and academic researchers to perform fast and scalable analyses to maximize the value of genomic data. Under the terms of the agreement, AstraZeneca will adopt Bina GMS globally to support enterprise genomic data analysis and management. Bina in turn will provide AstraZeneca with direct access to its scientific and engineering teams to further develop the Bina GMS for pharmaceutical applications.
|05:33 EDT||RHHBY||Inovio, Roche initiate clinical trial for DNA immunotherapy to treat HCB|
Inovio Pharmaceuticals (INO) announced that it has initiated a Phase I trial to evaluate Inovio's DNA immunotherapy in patients who are chronically infected with hepatitis B. In 2013, Roche (RHHBY) and Inovio entered into a partnership to co-develop and commercialize Inovio's hepatitis B immunotherapy. This trial initiation triggers a $3M milestone payment from Roche to Inovio. This phase I, randomized, open-label, active-controlled, dose escalation study will evaluate the safety, tolerability, and immunogenicity of Inovio's hepatitis B immunotherapy, INO-1800, alone or in combination with INO-9112, Inovio's IL-12-based immune activator. This international study will enroll patients in the United States and Asia Pacific region with a primary endpoint of safety and tolerability of the therapy. The secondary endpoints will evaluate the cellular and humoral immune response to INO-1800 and investigate the therapy's effect on several viral and antiviral parameters. All trial subjects are also medicated with standard-of-care antiviral therapies.
|April 17, 2015|
|05:32 EDT||RHHBY||Accelerate Diagnostics appoints Pete Bantock to Chief Culture Officer|
Accelerate Diagnostics (AXDX) appointed Pete Bantock to the newly created position of Chief Culture Officer and Head of Human Resources. Bantock was most recently the SVP and Head of commercial Operations for the Americas. He will be replaced by Ron Price, who joins the company from Roche (RHHBY) where he held the position of VP of Point of Care and Commercial Operations.
|April 16, 2015|
|08:04 EDT||RHHBY||Roche granted orphan status for lymphoma treatment|
The FDA granted Roche's Genentech unit orphan status for Gazyva, its treatment of follicular lymphoma.
|April 14, 2015|
|06:30 EDT||RHHBY||Roche to seek to have cancer drug tested in 11 trials in 2015, Reuters says|
Roche said it would seek to have its immunotherapy cancer drug, MPDL3280A, in 11 late stage trials by the end of 2015, aaccording to Reuters. The drug is being tested in melanoma, as well as lung, bladder, kidney, bowel and blood cancers, the news service noted. Reference Link
|April 13, 2015|
|10:01 EDT||RHHBY||Roche acquires CAPP Medical|
Roche announced it has acquired CAPP Medical, a genomics research company founded by Stanford University oncologists and industry veterans, to advance the development of technology for cancer screening and monitoring through the detection of circulating tumor DNA in blood.